Appendix C and Quarterly Activity Report

Imagion Biosystems today released its Appendix 4C Quarterly Cashflow report and update on company activities for the quarter ending 30 September 2020 (Q3 FY20).

Executive Chairman and CEO Bob Proulx said, “This is an exciting time for Imagion as we are on the cusp of commencing our MagSense® HER2 breast cancer Phase I study.”

“We enter this important phase with a stronger balance sheet, thanks to shareholders backing the capital raising during the quarter. We have the funds in place to see us through completion of the study and the opportunity to accelerate development of the technology and pipeline as we look to expand commercial opportunities for our MagSense® technology.”

Q3 Highlights:

  • Raised $4.7M (after costs) in over-subscribed placement with funds to be used to complete Phase I study and accelerate technology pipeline developments
  • Phase I study submitted for HREC review – approval received in early October
  • Manufacturing and clinical site preparations remain on schedule for the commencement of the MagSense® HER2 breast cancer Phase I study in the fourth calendar quarter as planned

Read the Quarter Activity Report.